Asia Pacific Immunohistochemistry Market: How Advanced Diagnostics Are Transforming Cancer Care
According to a new report by Polaris Market Research, the Asia
Pacific immunohistochemistry market was valued at USD 531.20 million
in 2024 and is projected to reach USD 1,218.85 million by 2034, expanding at a
CAGR of 8.7% over the forecast period. Growth is underpinned by the rising
prevalence of chronic disease, expanding adoption of personalized medicine, and
accelerating investment in diagnostic infrastructure across key end-use
industries.
What Is Driving Asia Pacific Immunohistochemistry Market
Growth?
Demand is climbing as the region's growing chronic disease
burden converges with rising healthcare expenditure across China, India, and
Australia. Manufacturers and clinical laboratories are prioritizing precise,
tissue-based biomarker detection, pushing immunohistochemistry (IHC) adoption
deeper into oncology, infectious disease screening, and companion diagnostics.
Polaris analysts note that cancer incidence in Asia stood at 169.1 per 100,000
people in 2020, accounting for roughly half of the global cancer burden,
positioning the segment for sustained double-digit growth through 2034, with
hospitals and diagnostic laboratories emerging as the largest revenue
contributor and the kits segment posting the fastest incremental gains.
Key Trends Shaping the Asia Pacific Immunohistochemistry
Industry
Rising Geriatric Population
Older adults face elevated risk of cancer, neurodegenerative
disorders, and cardiovascular disease, all of which rely on detailed tissue
diagnostics. The United Nations Population Fund projects India's 80+ population
will grow roughly 279% between 2022 and 2050, a demographic shift that is
steadily lifting demand for IHC-based disease characterization across regional
clinical labs.
Increasing Product Development and Launches
Companies across the region are introducing advanced
antibodies, automated staining systems, and multiplex assays that improve the
speed and reproducibility of IHC workflows. Multiplex platforms in particular
allow simultaneous detection of multiple biomarkers, supporting more
comprehensive disease profiling and broader adoption in both clinical and
research settings.
Regulatory Momentum in Companion Diagnostics
Recent regulatory clearances are reinforcing the
technology's role in precision oncology. In August 2025, Agilent secured US FDA
approval for its MMR IHC Panel pharmDx as a companion diagnostic identifying
dMMR colorectal cancer patients eligible for targeted immunotherapy, while
Roche obtained approval in May 2025 for an assay that enables patient selection
for a targeted NSCLC therapy — both signaling an outlook of tighter integration
between IHC testing and treatment decisions.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-immunohistochemistry-market
Market Segmentation: Breaking Down the Asia Pacific
Immunohistochemistry Market
Polaris segments the Asia Pacific immunohistochemistry
market by product, application, end use, and country, giving each buyer persona
a standalone, citable data point.
By Product
The antibodies segment led the market in 2024, supported by
its central role in detecting and analyzing cellular proteins for cancer
diagnostics across China, Japan, and India. The kits segment is projected to
expand at the fastest pace through 2034 as standardized, ready-to-use formats
simplify complex staining procedures and support high-throughput cancer
diagnostics.
By End Use
Hospitals and diagnostic laboratories accounted for the
largest revenue share in 2024, driven by rising cancer prevalence and continued
investment in advanced diagnostic tools and trained pathology personnel.
Research institutes continue to represent a meaningful and growing share as
academic and translational research expands across the region.
By Country
China led the market in 2024 on the strength of a rapidly
expanding healthcare system, substantial government investment in cancer
research, and the Healthy China 2030 initiative. India is projected to grow at
the fastest pace, propelled by its expanding population, rising cancer burden,
and government-backed programs such as Ayushman Bharat and Make in India that
are strengthening domestic diagnostic infrastructure.
Regional Outlook: Where Is the Immunohistochemistry
Market Growing Fastest?
China led the Asia Pacific market in 2024 on the back of
expanding healthcare infrastructure and a strong domestic biotechnology sector,
while India is expected to post the fastest CAGR through 2034, driven by rising
cancer awareness and expanding public and private healthcare access. Japan and
Australia round out the region's other significant markets, supported by
established diagnostic infrastructure and steady research funding.
Competitive Landscape: Leading Asia Pacific
Immunohistochemistry Companies
Key players profiled in the report include Agilent
Technologies, Inc., Cell Signaling Technology, Inc., Thermo Fisher Scientific
Inc., Roche Ltd., and Merck KGaA, among others, who are focusing on automation,
novel biomarker development, and strategic partnerships to strengthen market
position across the antibodies and hospital diagnostics segments outlined
above. Recent moves include Agilent's FDA companion-diagnostic approval and
Roche's VENTANA MET RxDx Assay clearance, both aimed at deepening share in precision
oncology across the region.
Why It Matters for Buyers Evaluating Market Entry
For stakeholders researching the Asia
Pacific immunohistochemistry market, this report benchmarks market
share, segment-level pricing, and forecast data — by product, application, end
use, and country — to support sourcing, investment, and go-to-market decisions.
It is built for procurement teams comparing suppliers, investors sizing entry
points, and strategy teams tracking multiplex assays as a growth adjacency.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research
and consulting firm offering 5,000+ published reports across 20+ industry
verticals, delivering data-backed insights to help businesses make informed
decisions.
More Trending Latest Reports By Polaris Market Research:
The
Secret Printing Technology Taking the Market by Storm - Microprinting
Power
Management Integrated Circuits Market
Comments
Post a Comment